Background: Arteriovenous malformation (AVM) is one of the cerebrovascular diseases that bear a high risk of hemorrhage. The treatment modalities include microsurgical resection, endovascular embolization, stereotactic radiosurgery, or combinations that vary widely. Several large series have been reported, while data from Asian populations were few. The aim of this study was to examine the efficacy of linear accelerator stereotactic radiosurgery (LINAC SRS) for the treatment of intracranial AVMs, to evaluate the hemorrhage rate and to analyze associated factors. Methods: One hundred and sixteen patients with AVM were treated with LINAC SRS in a single institute between September 1994 and May 2005 and were retrospectively evaluated. The demographics of patients, clinical characteristics of AVM, the treatment modalities, and the parameters of the LINAC SRS were analyzed. Delayed toxicity and hemorrhage rate after treatment were also evaluated. The AVM obliteration and bleed rates were calculated using the Kaplan-Meier method and Cox regression analyses. Results: The efficacy rate with total obliteration after treatment was 81.9% (95 of 116 patients). The median interval to achieve total obliteration was 49 months. Microsurgical resection combined with SRS for residual AVMs achieved better obliteration rates compared to SRS alone (statistically significant, p = 0.001), while no significant difference was found between the embolization group and the group with no prior treatment (p = 0.895). The Spetzler-Martin grade of AVM is a relative factor of obliteration, higher grades resulting in a worse outcome (p = 0.009). Obliteration was significantly influenced by AVM volume in univariate analysis (p = 0.034), and volume <5 cm3 contributed to improved obliteration (p = 0.01). There was no statistically significant difference in the hemorrhagic rate and the complication rate between ruptured and unruptured AVMs, while the unruptured group had a higher obliteration rate (p = 0.024). The annual hemorrhage rate after LINAC SRS treatment was 1.9%. The bleeding rate was 3.3% in the first year after radiosurgery, 2.1% in the second year, 1.9% between the second and fifth year, and 1.5% between the fifth and tenth year. Patients with hemorrhagic events before radiosurgery appeared to have a higher rebleeding risk during the latency period. Twenty-three patients (19.8%) had late adverse effects with regard to posttreatment radiological follow-up, but only 1 (0.8%) had newly developed neurological deficits. Conclusion: LINAC SRS achieved a high obliteration rate and reduced the risk of hemorrhage effectively in ruptured and unruptured intracranial AVMs. Prior microsurgical resection provided better outcome, while embolization showed no benefit. Adverse effects after treatment are acceptable and require long-term follow-up.

Keywords:
Arteriovenous malformation, Gamma knife, Linear accelerator, Radiosurgery, Stereotactic, Treatment, Intracranial hemorrhage
1.
Michelsen WJ: Natural history and pathophysiology of arteriovenous malformations. Clin Neurosurg 1979;26:307-313.
2.
Fleetwood IG, Steinberg GK: Arteriovenous malformations. Lancet 2002;359:863-873.
3.
The Arteriovenous Malformation Study Group: Arteriovenous malformations of the brain in adults. N Engl J Med 1999;340:1812-1818.
4.
Ondra SL, Troupp H, George ED, Schwab K: The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment. J Neurosurg 1990;73:387-391.
5.
Wedderburn CJ, van Beijnum J, Bhattacharya JJ: Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol 2008;7:223-230.
6.
van Beijnum J, van der Worp HB, Buis DR: Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA 2011;306:2011-2019.
7.
Friedlander RM: Arteriovenous malformations of the brain. N Engl J Med 2007;356:2704-2712.
8.
Steiner L, Leksell L, Greitz T, Forster DM, Backlund EO: Stereotaxic radiosurgery for cerebral arteriovenous malformations. Report of a case. Acta Chir Scand 1972;138:459-464.
9.
Stieg PE, Friedlander RM, Loeffler JS, Alexander E 3rd: Arteriovenous malformations: indications for stereotactic radiosurgery. Clin Neurosurg 2000;47:242-248.
10.
Blamek S, Tarnawski R, Miszczyk L: Linac-based stereotactic radiosurgery for brain arteriovenous malformations. Clin Oncol (R Coll Radiol) 2011;23:525-531.
11.
Koltz MT, Polifka AJ, Saltos A: Long-term outcome of Gamma Knife stereotactic radiosurgery for arteriovenous malformations graded by the Spetzler-Martin classification. J Neurosurg 2013;118:74-83.
12.
Chang JH, Chang JW, Park YG, Chung SS: Factors related to complete occlusion of arteriovenous malformations after gamma knife radiosurgery. J Neurosurg 2000;93(suppl 3): 96-101.
13.
Douglas JG, Goodkin R: Treatment of arteriovenous malformations using Gamma Knife surgery: the experience at the University of Washington from 2000 to 2005. J Neurosurg 2008;109(suppl):51-56.
14.
Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD: An analysis of the dose-response for arteriovenous malformation radiosurgery and other factors affecting obliteration. Radiother Oncol 2002;63:347-354.
15.
Flickinger JC, Pollock BE, Kondziolka D, Lunsford LD: A dose-response analysis of arteriovenous malformation obliteration after radiosurgery. Int J Radiat Oncol Biol Phys 1996;36:873-879.
16.
Friedman WA, Blatt DL, Bova FJ, Buatti JM, Mendenhall WM, Kubilis PS: The risk of hemorrhage after radiosurgery for arteriovenous malformations. J Neurosurg 1996;84:912-919.
17.
Liscak R, Vladyka V, Simonova G: Arteriovenous malformations after Leksell gamma knife radiosurgery: rate of obliteration and complications. Neurosurgery 2007;60:1005-1014.
18.
Friedman WA, Bova FJ, Bollampally S, Bradshaw P: Analysis of factors predictive of success or complications in arteriovenous malformation radiosurgery. Neurosurgery 2003;52:296-307.
19.
Zabel A, Milker-Zabel S, Huber P, Schulz-Ertner D, Schlegel W, Debus J: Treatment outcome after linac-based radiosurgery in cerebral arteriovenous malformations: retrospective analysis of factors affecting obliteration. Radiother Oncol 2005;77:105-110.
20.
Kasliwal MK, Kale SS, Gupta A: Does hemorrhagic presentation in cerebral arteriovenous malformations affect obliteration rate after gamma knife radiosurgery? Clin Neurol Neurosurg 2008;110:804-809.
21.
Yen CP, Sheehan JP, Schwyzer L, Schlesinger D: Hemorrhage risk of cerebral arteriovenous malformations before and during the latency period after GAMMA knife radiosurgery. Stroke 2011;42:1691-1696.
22.
Bambakidis NC, Selman WR: Stereotactic radiosurgery for arteriovenous malformations. J Neurosurg 2012;116:3-6; discussion 9-10.
23.
Orio P, Stelzer KJ, Goodkin R, Douglas JG: Treatment of arteriovenous malformations with linear accelerator-based radiosurgery compared with Gamma Knife surgery. J Neurosurg 2006;105(suppl):58-63.
24.
Starke RM, Komotar RJ, Hwang BY: A comprehensive review of radiosurgery for cerebral arteriovenous malformations: outcomes, predictive factors, and grading scales. Stereotact Funct Neurosurg 2008;86:191-199.
25.
Yamamoto M, Jimbo M, Hara M, Saito I, Mori K: Gamma knife radiosurgery for arteriovenous malformations: long-term follow-up results focusing on complications occurring more than 5 years after irradiation. Neurosurgery 1996;38:906-914.
26.
Zabel-du Bois A, Milker-Zabel S, Huber P, Schlegel W, Debus J: Linac-based radiosurgery or hypofractionated stereotactic radiotherapy in the treatment of large cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys 2006;64:1049-1054.
27.
Ellis TL, Friedman WA, Bova FJ, Kubilis PS, Buatti JM: Analysis of treatment failure after radiosurgery for arteriovenous malformations. J Neurosurg 1998;89:104-110.
28.
Meder JF, Oppenheim C, Blustajn J, et al: Cerebral arteriovenous malformations: the value of radiologic parameters in predicting response to radiosurgery. AJNR Am J Neuroradiol 1997;18:1473-1483.
29.
Blackburn SL, Ashley WW Jr, Rich KM: Combined endovascular embolization and stereotactic radiosurgery in the treatment of large arteriovenous malformations. J Neurosurg 2011;114:1758-1767.
30.
Gobin YP, Laurent A, Merienne L: Treatment of brain arteriovenous malformations by embolization and radiosurgery. J Neurosurg 1996;85:19-28.
31.
Andrade-Souza YM, Ramani M, Scora D, Tsao MN, terBrugge K, Schwartz ML: Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. Neurosurgery 2007;60:443-451; discussion 451-452.
32.
Kano H, Kondziolka D, Flickinger JC: Stereotactic radiosurgery for arteriovenous malformations after embolization: a case-control study. J Neurosurg 2012;117:265-275.
33.
Akakin A, Ozkan A, Akgun E: Endovascular treatment increases but gamma knife radiosurgery decreases angiogenic activity of arteriovenous malformations: an in vivo experimental study using a rat cornea model. Neurosurgery 2010;66:121-129; discussion 129-130.
34.
Sandalcioglu IE, Asgari S, Wende D, van de Nes JA, Dumitru CA, Zhu Y, Gizewski ER, Stolke D, Sure U: Proliferation activity is significantly elevated in partially embolized cerebral arteriovenous malformations. Cerebrovasc Dis 2010;30:396-401.
35.
Blamek S, Boba M, Larysz D: The incidence of imaging abnormalities after stereotactic radiosurgery for cerebral arteriovenous and cavernous malformations. Acta Neurochir Suppl 2010;106:187-190.
36.
Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ, for the international ARUBA Investigators: Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2013;13:62302-62308.
37.
Bruce EP, Michael JL, Robert DB: The risk of stroke or clinical impairment after stereotactic radiosurgery for ARUBA-eligible patients. Stroke 2013;44:437-441.
38.
Brown RD Jr, Wiebers DO, Forbes G: The natural history of unruptured intracranial arteriovenous malformations. J Neurosurg 1988;68:352-357.
39.
Crawford PM, West CR, Chadwick DW, Shaw MD: Arteriovenous malformations of the brain: natural history in unoperated patients. J Neurol Neurosurg Psychiatry 1986;49:1-10.
40.
Graf CJ, Perret GE, Torner JC: Bleeding from cerebral arteriovenous malformations as part of their natural history. J Neurosurg 1983;58:331-337.
41.
Jane JA, Kassell NF, Torner JC, Winn HR: The natural history of aneurysms and arteriovenous malformations. J Neurosurg 1985;62:321-323.
42.
Stapf C, Labovitz DL, Sciacca RR, Mast H, Mohr JP, Sacco RL: Incidence of adult brain arteriovenous malformation hemorrhage in a prospective population-based stroke survey. Cerebrovasc Dis 2002;13:43-46.
43.
Yamamoto M, Jimbo M, Kobayashi M: Long-term results of radiosurgery for arteriovenous malformation: neurodiagnostic imaging and histological studies of angiographically confirmed nidus obliteration. Surg Neurol 1992;37:219-230.
44.
Maruyama K, Kawahara N, Shin M: The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med 2005;352:146-153.
45.
Maruyama K, Shin M, Tago M, Kishimoto J, Morita A, Kawahara N: Radiosurgery to reduce the risk of first hemorrhage from brain arteriovenous malformations. Neurosurgery 2007;60:453-458.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.